I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients
153 Views
2 years ago
Trending
Memorial Sloan Kettering Cancer Center Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic Therapy
Liver Cancer
Eric J. Lehrer MD, MS @EricLehrer @IcahnMountSinai #ASTRO20 #livercancer The Development of Rib Fractures after Stereotactic Body Radiation Therapy to the Liver
Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 - LEAP-005: Phase II study of len plus pembro in pts with previously treated AST
John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib
Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma
Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential
Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor with a PDL1 inhibitor
Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato...
Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...
